PSP clinical subtypes have been related to the regional distribution and severity of pathogenic tau accumulation and neuronal loss.11 Although postmortem remains the gold standard for diagnosing PSP, recent publication of new diagnostic criteria from the Movement Disorder Society (MDS) PSP study group12 highlight the presence of PSP‐P and PAGF along with other PSP clinical phenotypes relating to underlying PSP pathology including PSP‐corticobasal (PSP‐CBS)13 and PSP‐frontal (PSP‐F) subtypes.14 Here, MAPT is linked to supranuclear palsy, progressive, 1.